ArticleCancer research communications2026

CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.

Daniela Criscuolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.